Endocrine therapy initiation and overall survival outcomes with omission of radiation therapy in older Medicare patients with early-stage hormone-receptor-positive breast cancer.
SEER-Medicare database
early-stage hormone-receptor-positive breast cancer
endocrine therapy initiation
older breast cancer patients
radiation therapy
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
revised:
08
10
2022
received:
19
08
2022
accepted:
17
11
2022
medline:
5
4
2023
pubmed:
27
11
2022
entrez:
26
11
2022
Statut:
ppublish
Résumé
Guidelines allow for the omission of radiotherapy in older women with early-stage, hormone-receptor-positive breast cancer, given that the patients receive adequate endocrine therapy (ET). However, the initiation of ET and survival outcomes after forgoing radiation therapy among these patients have not been well-studied. We identified patients aged 70 to 90 years old newly diagnosed in 2010-2015 with early-stage, hormone receptor positive, and human epidermal growth factor receptor 2 (HER2) negative (HR+/Her2-) breast cancer who received lumpectomy and omitted radiation therapy using the SEER-Medicare database. We examined the initiation of ET and the utilization patterns of ET using a multivariable logistic regression. We further examined the overall survival outcomes using Kaplan-Meier estimation and Cox proportional hazard model with inverse probability weighting. Of the 2618 patients, 808 (30.9%) received no ET. The multivariable logistic regression showed that more recent years had better ET initiation (2013-2015 vs. 2010-2012: OR = 1.39, 95% CI:[1.16, 1.66]), while older patients (81-90 vs. 70-80: OR = 0.45, 95% CI:[0.38, 0.54]) were less likely to receive ET. Both the Kaplan-Meier estimation (log-rank p-value<0.0001) and the Cox proportional hazard model with inverse probability weighting (HR = 0.76, 95% CI:[0.58, 0.99]) showed that receiving ET was associated with better overall survival. This population-based study suggests that a sizable proportion of patients who omitted radiation did not receive endocrine therapy and receiving endocrine therapy was beneficial among these patients. Although ET initiation has improved in more recent years, certain patient groups were still especially susceptible to no endocrine therapy.
Sections du résumé
BACKGROUND
Guidelines allow for the omission of radiotherapy in older women with early-stage, hormone-receptor-positive breast cancer, given that the patients receive adequate endocrine therapy (ET). However, the initiation of ET and survival outcomes after forgoing radiation therapy among these patients have not been well-studied.
METHODS
We identified patients aged 70 to 90 years old newly diagnosed in 2010-2015 with early-stage, hormone receptor positive, and human epidermal growth factor receptor 2 (HER2) negative (HR+/Her2-) breast cancer who received lumpectomy and omitted radiation therapy using the SEER-Medicare database. We examined the initiation of ET and the utilization patterns of ET using a multivariable logistic regression. We further examined the overall survival outcomes using Kaplan-Meier estimation and Cox proportional hazard model with inverse probability weighting.
RESULTS
Of the 2618 patients, 808 (30.9%) received no ET. The multivariable logistic regression showed that more recent years had better ET initiation (2013-2015 vs. 2010-2012: OR = 1.39, 95% CI:[1.16, 1.66]), while older patients (81-90 vs. 70-80: OR = 0.45, 95% CI:[0.38, 0.54]) were less likely to receive ET. Both the Kaplan-Meier estimation (log-rank p-value<0.0001) and the Cox proportional hazard model with inverse probability weighting (HR = 0.76, 95% CI:[0.58, 0.99]) showed that receiving ET was associated with better overall survival.
CONCLUSION
This population-based study suggests that a sizable proportion of patients who omitted radiation did not receive endocrine therapy and receiving endocrine therapy was beneficial among these patients. Although ET initiation has improved in more recent years, certain patient groups were still especially susceptible to no endocrine therapy.
Identifiants
pubmed: 36428284
doi: 10.1002/cam4.5488
pmc: PMC10067080
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6935-6944Informations de copyright
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351:971-977.
Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31:2382-2387.
Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015;16:266-273.
National Comprehensive Cancer Network Clinical Practice Guidelines in Breast Cancer Version 2.2022 https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed April 14, 2022.
Shen X, Anne PR, Keith SW, et al. Radiation therapy use and outcomes among older women with ER-positive and ER-negative stage I breast cancer. Am J Clin Oncol. 2014;37:241-247.
Rhieu BH, Rajagopalan MS, Sukumvanich P, et al. Patterns of care for omission of radiation therapy for elderly women with early-stage breast cancer receiving hormonal therapy. Pract Radiat Oncol. 2015;5:e267-e273.
Palta M, Palta P, Bhavsar NA, Horton JK, Blitzblau RC. The use of adjuvant radiotherapy in elderly patients with early-stage breast cancer: changes in practice patterns after publication of cancer and leukemia group B 9343. Cancer. 2015;121:188-193.
Chu QD, Zhou M, Medeiros KL, Peddi P, Wu XC. Impact of CALGB 9343 trial and sociodemographic variation on patterns of adjuvant radiation therapy practice for elderly women (≥70 years) with stage I, estrogen receptor-positive breast cancer: analysis of the National Cancer Data Base. Anticancer Res. 2017;37:5585-5594.
Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365:60-62.
National Cancer Institute. Surveillance, Epidemiology, and End Results Program. https://seer.cancer.gov/. Accessed March 18, 2022.
Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173:676-682.
Schaffar R, Rapiti E, Rachet B, Woods L. Accuracy of cause of death data routinely recorded in a population-based cancer registry: impact on cause-specific survival and validation using the Geneva cancer registry. BMC Cancer. 2013;13:609.
Daly B, Olopade OI, Hou N, Yao K, Winchester DJ, Huo D. Evaluation of the quality of adjuvant endocrine therapy delivery for breast cancer Care in the United States. JAMA Oncol. 2017;3:928-935.
Tamirisa N, Lin H, Shen Y, et al. Impact of adjuvant endocrine therapy in older patients with comorbidities and estrogen receptor-positive, node-negative breast cancer-a National Cancer Database analysis. Cancer. 2021;127:2196-2203.
Warren JL, Butler EN, Stevens J, et al. Receipt of chemotherapy among medicare patients with cancer by type of supplemental insurance. J Clin Oncol. 2015;33:312-318.
Doll KM, Meng K, Basch EM, Gehrig PA, Brewster WR, Meyer AM. Gynecologic cancer outcomes in the elderly poor: a population-based study. Cancer. 2015;121:3591-3599.
Guadagnolo BA, Liao KP, Giordano SH, Elting LS, Shih YC. Variation in intensity and costs of care by payer and race for patients dying of cancer in Texas: an analysis of registry-linked Medicaid, Medicare, and dually eligible claims data. Med Care. 2015;53:591-598.
Wu XC, Lund MJ, Kimmick GG, et al. Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. J Clin Oncol. 2012;30:142-150.
Freedman RA, Virgo KS, He Y, et al. The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer. 2011;117:180-189.
Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34:3661-3679.
Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28:4120-4128.
Blanchette PS, Lam M, Richard L, et al. Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario. Canada Breast Cancer Res Treat. 2020;179:217-227.
Brooks GA, Hoverman JR, Colla CH. The affordable care act and cancer care delivery. Cancer J. 2017;23:163-167.
Hershman DL, Tsui J, Wright JD, Coromilas EJ, Tsai WY, Neugut AI. Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer. J Clin Oncol. 2015;33:1053-1059.
Henry NL, Azzouz F, Desta Z, et al. Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol. 2012;30:936-942.
Aiello Bowles EJ, Boudreau DM, Chubak J, et al. Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J Oncol Pract. 2012;8:e149-e157.
Bender CM, Gentry AL, Brufsky AM, et al. Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer. Oncol Nurs Forum. 2014;41:274-285.
Bickell NA, Weidmann J, Fei K, Lin JJ, Leventhal H. Underuse of breast cancer adjuvant treatment: patient knowledge, beliefs, and medical mistrust. J Clin Oncol. 2009;27:5160-5167.
Alzahrani M, Clemons M, Chang L, et al. Management strategies for older patients with low-risk early-stage breast cancer: a physician survey. Curr Oncol. 2021;29:1-13.
Chalela P, Munoz E, Inupakutika D, et al. Improving adherence to endocrine hormonal therapy among breast cancer patients: study protocol for a randomized controlled trial. Contemp Clin Trials Commun. 2018;12:109-115.
Krok-Schoen JL, Naughton MJ, Young GS, et al. Increasing adherence to adjuvant hormone therapy among patients with breast cancer: a smart phone app-based pilot study. Cancer Control. 2019;26:1073274819883287.
Savelberg W, van der Weijden T, Boersma L, Smidt M, Willekens C, Moser A. Developing a patient decision aid for the treatment of women with early stage breast cancer: the struggle between simplicity and complexity. BMC Med Inform Decis Mak. 2017;17:112.
Keim-Malpass J, Anderson RT, Balkrishnan R, Desai RP, Showalter SL. Evaluating the long-term impact of a cooperative group trial on radiation use and adjuvant endocrine therapy adherence among older women. Ann Surg Oncol. 2020;27:3458-3465.